Product logins

Find logins to all Clarivate products below.


Mild Cognitive Impairment – Epidemiology – Asia Pacific

We review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on MCI.

We summarize the results of our review for the epidemiological estimates of prevalence that are used directly in our forecast model in the “Studies Included” table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the sources table in the relevant epidemiology population sections. We report the most relevant sources not used and the reason for not using them in the “Studies Excluded” table

Related Market Assessment Reports

Report
Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s Leqembi (lecanemab) has launched for the treatment of early AD in the United States and Japan. Although EMA’s CHMP has approved the drug EC’s approval is still pending. Eli…
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The treatment landscape for multiple sclerosis (MS) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (DMTs) available and more in development. The market…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…